A randomized, double-blind, double-dummy, controlled, multicenter study of Qingzhong (tenofovir disoproxil fumarate) versus Viread for the treatment of chronic hepatitis B: First-stage results at week 48

BACKGROUND: Tenofovir disoproxil fumarate (TDF) has been widely recommended as a first-line antiviral agent to treat chronic hepatitis B (CHB). Qingzhong and Viread, formulations of TDF commercialized by Jiangsu Chia-tai Tianqing Pharmaceutical Co Ltd and GlaxoSmithKline, respectively, have both bee...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Rong-Yue, Xu, Jing-Hang, Si, Chong-Wen, Wang, Sa, Shang, Jia, Yu, Zu-Jiang, Mao, Qing, Xie, Qing, Zhao, Wei, Li, Jun, Gao, Zhi-Liang, Wu, Shan-Ming, Tang, Hong, Cheng, Jun, Chen, Xin-Yue, Zhang, Wen-Hong, Wang, Hao, Xu, Zhong-Nan, Wang, Ling, Dai, Jun, Yu, Yan-Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
3700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6831396/
https://www.ncbi.nlm.nih.gov/pubmed/31415381
http://dx.doi.org/10.1097/MD.0000000000016778

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6831396/
https://www.ncbi.nlm.nih.gov/pubmed/31415381
http://dx.doi.org/10.1097/MD.0000000000016778

Ejemplares similares